Collaborations (Tables)

9 Months Ended

Sep. 30, 2013

Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table Text Block]

The following table summarizes the composition of our total revenue recognized from all transactions, including collaboration activity:

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2013		2012		2013		2012
Net product sales	$	5,589.2	$	5,301.2	$	16,797.6	$	16,170.5
Collaboration and other revenue	183.4		142.1		506.7		475.5
Total revenue	$	5,772.6	$	5,443.3	$	17,304.3	$	16,646.0

Erbitux [Member]

Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table Text Block]

The following table summarizes the revenue recognized with respect to Erbitux:

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2013		2012		2013		2012
Net product sales	$	6.2	$	6.2	$	43.8	$	69.0
Collaboration and other revenue	81.0		80.4		229.9		241.0
Total revenue	$	87.2	$	86.6	$	273.7	$	310.0

Exenatide [Member]

Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table Text Block]

The following table summarizes the revenue and other income recognized with respect to exenatide: 

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2013		2012		2013		2012
Net product sales	$	28.6	$	49.5	$	113.7	$	151.1
Collaboration and other revenue	—		4.7		—		70.1
Total revenue	$	28.6	$	54.2	$	113.7	$	221.2
Income related to termination of the exenatide collaboration with Amylin (1)	$	—	$	787.8	$	495.4	$	787.8